Nutrition Recommendations for Breast Cancer Patients on Aromatase Inhibitors

Introduction to Nutrition Guidelines

The American Society for Nutrition and the European Society for Clinical Nutrition and Metabolism (ESPEN) recommend against the use of ketogenic diets for breast cancer patients on aromatase inhibitors due to lack of clinical evidence and potential for malnutrition and muscle loss 1, 2, 3

Breast cancer patients on aromatase inhibitors should follow a moderate calorie restriction (500-1000 kcal/day reduction when appropriate) with a balanced macronutrient distribution: <30% fat, >55% carbohydrates from whole foods, and 1.2-1.5 g protein/kg/day to prevent sarcopenic obesity 4, 6
The American Heart Association recommends 5-9 servings/day of fruits and vegetables (fruits ~150g/serving, vegetables ~75g/serving) 4, 6

The National Cancer Institute recommends targeting 5-10% weight loss over 6-12 months if overweight or obese, which reduces cardiovascular risk factors without compromising lean mass 4, 9
Aim for 0.5-1 kg/week weight loss through combined dietary modification and physical activity 4

The American College of Cardiology recommends monitoring lipid levels as standard practice for high-risk populations 7, 8
Educate patients on lifestyle modifications including smoking cessation, diet, and exercise to reduce cardiotoxicity risk 7, 8

The European Association for the Study of Diabetes recommends considering GLP-1 receptor agonists (tirzepatide or semaglutide) for breast cancer patients on aromatase inhibitors with significant weight gain or insulin resistance, as they provide evidence-based metabolic benefits without malnutrition risk 11
GLP-1 receptor agonists can achieve 15-21% body weight loss while preserving lean mass when combined with resistance training, improve insulin sensitivity and glycemic control, and provide 26% reduction in cardiovascular events 11